Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2015.

The Company reported a net loss of $2.6 million for the third quarter of 2015 or $0.23 per diluted share, compared to net loss of$2.9 million or $0.30 per diluted share for the same period in 2014. Revenues for the quarter were $210 thousand compared to$145 thousand in the third quarter of 2014.

Research and development expenses associated with product candidates utilizing the Company’s LIMITX, and IMPEDE® Technologies were $0.4 million in the third quarter of 2015, compared to $1.0 million for the same period in 2014. Selling, marketing, general and administrative expenses were $2.0 million in the third quarter of 2015, versus $1.7 million in the same period last year. Selling and marketing expenses primarily consist of advertising and marketing activities for NEXAFED® and NEXAFED® SINUS.

The Company reported a net loss of $4.1 million for the nine months ended September 30, 2015 or $0.39 per diluted share, compared to net loss of $10.5 million or $1.08 per diluted share for the same period in 2014. Revenues for the nine months ended September 30, 2015 were $5.9 million compared to $222 thousand in the same period last year. The 2015 results reflect the $5.0 million payment arising from licensing OXAYDO (oxycodone HCI) tablets to Egalet Corporation (NASDAQ: EGLT)entities.

Research and development expenses associated with product candidates utilizing the Company’s LIMITX, and IMPEDE® Technologies were $1.9 million in the nine months ended September 30, 2015, compared to $3.7 million for the same period in 2014 for the Company’s LIMITX, AVERSION® and IMPEDE® Technologies. Selling, marketing, general and administrative expenses were $6.4 million in the nine months ended September 30, 2015, versus $5.9 million in the same period last year. Selling and marketing expenses primarily consisted of advertising and marketing activities for NEXAFED® and NEXAFED® SINUS.

In October 2015, the Company received a $2.5 million milestone payment from Egalet Corporation triggered by the first commercial shipments of OXAYDO. As of October 30, 2015, our unrestricted cash, cash equivalents and marketable securities, less our compensating balance requirement of $2.5 million, was approximately $14.0 million, and our outstanding loan balance with Oxford Finance LLC was $8.6 million.

In August 2015, the Company effected a 1-for-5 reverse stock split of its common stock. All share amounts and per share data (other than the par value and number of authorized shares) in this earnings release and the accompanying condensed consolidated financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split. As a result of the reverse stock split, the Company regained compliance with the minimum bid price requirement for continued listing on theNASDAQ Capital Market in September 2015. (Original Source)

Shares of Acura closed today at $2.67, up $0.06 or 2.22%. ACUR has a 1-year high of $6.75 and a 1-year low of $2.05. The stock’s 50-day moving average is $2.61 and its 200-day moving average is $3.53.

Acura Pharmaceuticals Inc is a pharmaceutical company. It is engaged in the research, development & manufacture of product to address medication abuse & misuse, utilizing the Company’s proprietary, tamper-resistant AVERSION & IMPEDE technology platforms.